Navigation Links
InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
Date:2/2/2009

BRISBANE, Calif., Feb. 2 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will report results from its Phase 3 CAPACITY program of pirfenidone in idiopathic pulmonary fibrosis (IPF) prior to market open on Tuesday, February 3. InterMune will conduct a conference call and webcast, with accompanying slide presentation, to discuss results from the CAPACITY program at 8:00 a.m. EST (5:00 a.m. PST) on Tuesday, February 3.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 84164912. To access the live webcast of the conference call, with accompanying slides, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 84164912.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio in
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
8. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
9. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
10. InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... MARLBOROUGH, Mass. , Aug. 30, 2014 /PRNewswire/ ... from its NEural Cardiac TherApy foR Heart Failure ... sham-controlled clinical trial investigating vagus nerve stimulation (VNS) ... Zannad, M.D., Ph.D., Professor of Therapeutics and Cardiology ... the Institut National de la Sante et de ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... -- Market Research Report on Global and Chinese ... and in-depth market survey on Global and ... firstly reviews the basic information of X-Ray Crystallography ... The report then explores global and China,s top ... specification, capacity, Production value, and market share etc. ...
Breaking Medicine Technology:Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5
... 8, 2011 K-V Pharmaceutical Company (NYSE: KV.A/ KV.B) (the ... ® , the only U.S. Food & Drug Administration ("FDA") ... in women with singleton pregnancy who have a history of ... was launched during March of 2011. From its launch date ...
... 8, 2011 Thompson MIS is pleased to announce ... "Best New Technology for Spine Care in 2011" award ... the company during the annual meeting of the North ... is a patented system that enables surgeons to more ...
Cached Medicine Technology:K-V Pharmaceutical Announces Updated Makena® Performance Metrics 2K-V Pharmaceutical Announces Updated Makena® Performance Metrics 3K-V Pharmaceutical Announces Updated Makena® Performance Metrics 4K-V Pharmaceutical Announces Updated Makena® Performance Metrics 5K-V Pharmaceutical Announces Updated Makena® Performance Metrics 6K-V Pharmaceutical Announces Updated Makena® Performance Metrics 7K-V Pharmaceutical Announces Updated Makena® Performance Metrics 8
(Date:8/30/2014)... 2014 Ticket Down reports that ticket ... match next Saturday at Levi's Stadium. The summer months ... in the United States due to the fact that so many ... major city. Many of these games were practice games in ... summer. , Levi’s Stadium is a brand new facility that will ...
(Date:8/30/2014)... Colorado (PRWEB) August 30, 2014 Patients ... for this disorder in a new review published by ... condition to deal with, so there is no wonder ... overcome it. The Natural Vitiligo Treatment is one of ... The Natural Vitiligo Treatment promises to stop the spread ...
(Date:8/30/2014)... The Plastic Surgery Group (PSG) is ... even in the U.S. to provide clients with Vanquish, ... patients’ waists with deep-tissue heating. , Unlike Cryotherapy which ... is more inclusive to target large sections of desired ... panels about one inch away from their body while ...
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Seniors Guide, the ... recently that focus on Alzheimer’s Disease, Dementia, and Memory ... to the public of being diagnosed with the Alzheimer’s, inspired ... movie, “I’ll Be Me”. The movie, out on October ... focusing on his diagnosis of the disease – which inspires ...
Breaking Medicine News(10 mins):Health News:Mexico vs. Chile Tickets at Levi's Stadium in Santa Clara, CA: TicketDown.com Offers Promo Code for Mexico vs. Chile Exhibition Game on September 6th 2Health News:Natural Vitiligo Treatment Review Exposes Fast Method for Skin Repigmentation 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2
... The American Academy of Family Physicians today announced the ... first alliance partner, The Coca-Cola Company. , (Logo: ... is a program that allows corporate partners like The ... consumers about the role their products can play in ...
... are not addressing the main differences between neighborhood food ... or reduce obesity, according to a new RAND Corporation study. ... Angeles region has no more fast-food chain establishments on a ... rather many more small food stores and other food outlets. ...
... The founders of HEAL Africa ( www.hea ... nonprofit organization that provides holistic healing including urgent care medical services ... of Congo, are conducting a seven-city tour of the U.S. to ... of war in Congo. HEAL Africa,s approach to healing conflict has ...
... ,Symphony of the Superhero, to Feature DJ Cut Chemist, Violinist ... Boychoir, Whittier Elementary Choir, The Raretones and Bells of the ... The Symphony Guild today announced ... the Superhero, an annual event which benefits Seattle ...
... in some, but effects were fleeting, scientists say , MONDAY, ... addicts beat their habit is showing some effect but is ... one-third of participants in a new study developed desired immune ... cocaine use did go down. But the effects were only ...
... ... competitive advantage , ... (PRWEB) October 5, 2009-- BodyMedia, Inc. , the pioneer in developing wearable body monitoring ... Ki Performance. Through the company,s first strategic partner in Europe, BodyMedia is extending its ...
Cached Medicine News:Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 2Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 3Health News:The American Academy of Family Physicians Launches Consumer Alliance With First Partner: The Coca-Cola Company 4Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 2Health News:Los Angeles fast-food restaurant ban unlikely to cut obesity, study finds 3Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 2Health News:HEAL Africa's Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 3Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 2Health News:The Symphony Guild Announces Artist Lineup for 2009 Event 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 2Health News:BodyMedia, Inc. Expands Overseas Offerings and Receives Milestone Certification for Continued Global Growth 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: